‘Brainless’ US MFN Policy Could Drive Pharma Investment To Europe

 
• By Francesca Bruce

European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.

Plans for a most favored nations drug pricing policy are creating an unpredictable environment, which may drive investment to Europe. (Shutterstock)

More from Pricing Debate

More from Market Access